Rosetta Genomics (FRA:RQ1) Total Stockholders Equity : €0.98 Mil (As of Jun. 2017)

View and export this data going back to 2014. Start your Free Trial

What is Rosetta Genomics Total Stockholders Equity?

Rosetta Genomics's Total Stockholders Equity for the quarter that ended in Jun. 2017 was €0.98 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Rosetta Genomics's Book Value per Share for the quarter that ended in Jun. 2017 was €0.38. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Rosetta Genomics's Debt-to-Equity for the quarter that ended in Jun. 2017 was 2.23.

Rosetta Genomics Total Stockholders Equity Historical Data

The historical data trend for Rosetta Genomics's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rosetta Genomics Total Stockholders Equity Chart

Rosetta Genomics Annual Data

Trend

Dec07

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Total Stockholders Equity

Get a 7-Day Free Trial

23.55

17.25

12.22

18.01

4.19

Rosetta Genomics Quarterly Data
	Dec10	Mar11	Jun11	Dec11	Jun12	Dec12	Jun13	Dec13	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Jun17
Total Stockholders Equity	Get a 7-Day Free Trial															14.20	11.26	7.95	4.19	0.98

Rosetta Genomics (FRA:RQ1) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Rosetta Genomics's Book Value per Share for the quarter that ended in Jun. 2017 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(0.978	-	0)	/	2.58809
	=	0.38

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Rosetta Genomics's Debt-to-Equity for the quarter that ended in Jun. 2017 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.049	+	2.131)	/	0.978
	=	2.23

Rosetta Genomics Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Rosetta Genomics's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Rosetta Genomics (FRA:RQ1) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Rosetta Genomics Ltd (FRA:RQ1) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

10 Plaut Street, Science Park, Rehovot, ISR, 76706

Website

http://www.rosettagenomics.com

Rosetta Genomics Ltd is an Israel based genomic diagnostics company operating globally. It is focused on research and development on diagnostics and therapeutics in the field of microRNAs. The firm markets and sells four diagnostic tests based on its microRNA technologies namely, RosettaGX Cancer Origin for the identification of the primary site of metastatic cancer, mi-LUNG, mi-KIDNEY which is a microRNA-based kidney tumor classification test for pathology samples and RosettaGx Reveal which is a microRNA-based assay for the diagnosis of indeterminate thyroid fine-needle aspirate samples. Its revenues include Clinical testing revenues and Licensing revenues, of which Clinical testing revenue is maximum. The group generates its revenues mainly from diagnosing patient tissue.

Rosetta Genomics (FRA:RQ1) Headlines

No Headlines